Home ›
Entities
› academia
› Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
Research article (Current Oncology, 2021) · cited 14× · AI/ML
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
Summary
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group is a scholarly article[1].
Key Facts
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Retrieved May 24, 2026, from https://4ort.xyz/entity/considerations-for-developing-a-reassessment-process-report-from-the-canadian-real-world-evidence-for-value-of-cancer-dr
MLA“Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/considerations-for-developing-a-reassessment-process-report-from-the-canadian-real-world-evidence-for-value-of-cancer-dr.
BibTeX@misc{4ortxyz_considerations-for-developing-a-reassessment-process-report-from-the-canadian-real-world-evidence-for-value-of-cancer-dr_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group}}, year = {2026}, url = {https://4ort.xyz/entity/considerations-for-developing-a-reassessment-process-report-from-the-canadian-real-world-evidence-for-value-of-cancer-dr}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group — https://4ort.xyz/entity/considerations-for-developing-a-reassessment-process-report-from-the-canadian-real-world-evidence-for-value-of-cancer-dr (retrieved 2026-05-24)
